等待開盤 02-06 09:30:00 美东时间
-0.110
-1.45%
Certara Inc. (Nasdaq: CERT), a global leader in model-informed drug development, will release its 2025 fourth-quarter and full-year financial results on February 26, 2026. Management will host a conference call at 8:30 AM ET, requiring investors to register online in advance. A live and archived webcast will be available on Certara's investor website.
01-29 13:30
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
01-27 20:40
今日重点评级关注:HC Wainwright & Co.:维持奥麦罗制药"买入"评级,目标价从20美元升至40美元;HC Wainwright & Co.:维持Cullinan Therapeutics"买入"评级,目标价从26美元升至27美元
01-09 20:22
今日重点评级关注:HC Wainwright & Co.:维持MetaVia Inc."买入"评级,目标价从12美元升至40美元;Canaccord Genuity:维持GH Research"买入"评级,目标价从35美元升至39美元
01-07 17:25
Throughout the last three months, 6 analysts have evaluated Certara (NASDAQ:CER...
01-07 04:01
Leerink Partners analyst Michael Cherny upgrades Certara (NASDAQ:CERT) from Market Perform to Outperform and announces $13 price target.
01-07 03:46
今日重点评级关注:Ascendiant Capital:维持Society Pass"买入"评级,目标价从22美元升至22.5美元;HC Wainwright & Co.:维持Climb Bio"买入"评级,目标价从9美元升至11美元
2025-12-19 10:15
Morgan Stanley analyst Sean Laaman maintains Certara (NASDAQ:CERT) with a Equal-Weight and lowers the price target from $16 to $12.
2025-12-19 01:42
今日重点评级关注:HC Wainwright & Co.:维持BioCryst Pharma"买入"评级,目标价从30美元升至32美元;TD Cowen:上调Milestone Pharmaceuticals评级至"买入",目标价8美元
2025-12-16 09:36
今日重点评级关注:杰富瑞:维持ImmunityBio Inc Ordinary Shares"买入"评级,目标价从8美元升至9美元;B. Riley证券:维持WAVE Life Sciences"买入"评级,目标价从19美元升至37美元
2025-12-15 15:30